Press Release Tokyo Future Style, Inc, April 20th 2017

Tokyo Future Style signs Distribution Agreement with Radboud University
medical center, for the introduction of the human renal cell lines to use intransporter assays and drug toxicity screening which have beendeveloped by the university.

Tokyo Future Style, Inc (Tsukuba City, Japan) and Radboud University Medical Center(Nijmegen, the Netherlands) are pleased to announce having signed an agreement for
distribution of human Renal cell lines that allow drug transport and drug toxicity
screening developed by the university in Japan and Asian market.

Reliable prediction of drug-induced organ injury is a major issue during drugdevelopment. One

out of three

newly developed compounds leads to organ toxicity.

Regarding drug-induced kidney injury, one

out of fivecompounds leads to renal

toxicity during phase-3 of drug development. The proximal tubular (PT) epithelium isresponsible for reabsorption of filtered solutes and excretion of waste products andxenobiotics. The excretion of drugs is facilitated by drug transporters expressed on PT
epithelial cells (PTEC). Consequently, PTEC is sensitive to drug-induced renal toxicity.
Currently available PTECs have variable characteristics or express only a few drugtransporters. On the other hand, primary PTEC can only yield a limited amount ofmaterial, as proliferation stops after a few passages and the cells dedifferentiate. Suchmodels are not useful for highly predictive drug toxicity screening.
To overcome the limited availability of functional human PTEC, Radboud university
medical center has developed a human cell model with PT characteristics, including
multiple influx and efflux transporters, named conditionally immortalized human renal
proximal tubule epithelial cell line (ciPTEC). ciPTEC is developed by using both SV40
large T antigen and hTERT to accomplish conditionally immortalization. ciPTEC
maintains PT characteristics and proliferates for at least 60 passages. Further, ciPTEC
stably expresses the functional drug transporters OCT2, MRP2/4, BCRP and Pgp,

together with a functional receptor mediated endocytosis machinery. In addition, a next
generation ciPTEC was developed with stably and functional OAT1 and OAT3 transport,
completing the relevant renal drug transporter expression. Therefore ciPTEC,ciPTEC-OAT1 and ciPTEC-OAT3 are excellent tools for the identification ofdrug-induced renal toxicity and the prediction of potential drug-drug interactions inpharmacological research. ciPTEC is currently gathering many attentions as a novel
platform for toxicity testing of lead compounds during drug development.
Features of ciPTEC• Human origin• Endogenous and stable expression of most renal transporters• Stably introduced OAT1 and OAT3
• Functional assays for DDI and toxicity• Stable for up to 60 passage numbers• > 25 scientific publications in the fields of pharmacology, pathology and physiologyApplications for ciPTEC• Drug-drug interaction studies• Influx assays (OCT2, OAT1/3)• Efflux assays (Pgp, BCRP, MRP4)• Cell toxicity• Phosphate reabsorption• Receptor mediated endocytosis (megalin, cubilin)

ciPTEC: stable expression of relevantrenal drug transporters.
From now, Tokyo Futue Style, Inc. will mediate for licensing the cell lines, , further,
mediating the custom service project at the university.

About Radboud University and Radboud UMC
Radboud university medical center is a leading academic center for patient care,education and research, with the mission ‘to have a significant impact on healthcare’.
Our activities help to improve healthcare and consequently the health of individuals
and of society. We believe we can achieve that by providing excellent quality,
participatory and personalized healthcare, operational excellence and by working
together in sustainable networks.
Contact information University:

Pieter Lomans
Press officer
Pieter.Lomans@radboudumc.nl
M +31 (0)6 31970558

About Tokyo Future Style, Inc.
Tokyo Future Style, Inc. is an international trading and marketing company located inthe Tokyo area. TFS mission is to market and distribute novel and unique products andservices from foreign biotech companies to academic and government institutions, andto research and development laboratories of major pharmaceutical, diagnostic andbiotech companies in Japan and Taiwan.
Contact for this article:

Takashi Endo /CEOTokyo Future Style, Inc.

+81-29-851-9222

endo@tokyofuturestle.com